Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7874337 | 0.93 | PDE5A (0.57) | PDE5A | |
| SCHEMBL8212990 | 0.92 | PDE5A (0.51) | PDE5A | |
| SCHEMBL8363356 | 0.91 | PDE5A (0.51) | PDE5A | |
| SCHEMBL6628887 | 0.90 | PDE5A (0.55) | PDE5A | |
| SCHEMBL10201564 | 0.90 | PDE5A (0.50) | PDE5A | |
| SCHEMBL14199888 | 0.90 | PDE5A (0.50) | PDE5A | |
| SCHEMBL7886157 | 0.88 | PDE5A (0.51) | PDE5A | |
| SCHEMBL8210189 | 0.85 | PDE5A (0.56) | PDE5A | |
| SCHEMBL8216613 | 0.84 | PDE5A (0.57) | PDE5A | |
| SCHEMBL16298439 | 0.84 | PDE5A (0.57) | PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9468637-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9198924-B2 | Organic compounds | INTRA-CELLULAR THERAPIES, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| US-20120053190-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC | 2012-03-01 | — | — | US | disclosed |
| US-20100087450-A1 | ORGANIC COMPOUNDS | INTRA-CELLULAR THERAPIES, INC. (US) | 2010-04-08 | — | — | US | disclosed |
| EP-1421084-B1 | POLYCYCLIC GUANINE PHOSPHODIESTERASE V INHIBITORS | SCHERING CORP (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1790652-A1 | Polycyclic guanine phosphodiesterase V inhibitors | Schering Corporation (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2003020724-A1 | POLYCYCLIC GUANINE PHOSPHODIESTERASE V INHIBITORS | SCHERING CORPORATION (US) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053190-A1 | ORGANIC COMPOUNDS | PDE5A, PDE4A, PDE3A | PDE5A 1/4885 |
| US-20100087450-A1 | ORGANIC COMPOUNDS | PDE3A, PDE5A, PDE2A | PDE5A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.